

Andrea Ciarmiello

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5544324/publications.pdf>

Version: 2024-02-01

93
papers

2,509
citations

236912

25
h-index

206102

48
g-index

98
all docs

98
docs citations

98
times ranked

3398
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Tracer Retention Levels on Visual Analysis of Cerebral [18F]-Florbetaben Pet Images. Current Radiopharmaceuticals, 2021, 14, 70-77.	0.8	1
2	Toward the Discovery and Development of PSMA Targeted Inhibitors for Nuclear Medicine Applications. Current Radiopharmaceuticals, 2020, 13, 63-79.	0.8	40
3	Longitudinal cognitive decline in mild cognitive impairment subjects with early amyloid- β^2 neocortical deposition. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2090-2098.	6.4	11
4	The brain cognitive reserve hypothesis: A review with emphasis on the contribution of nuclear medicine neuroimaging techniques. Journal of Cellular Physiology, 2019, 234, 14865-14872.	4.1	15
5	Sensitivity of fluorine-18-fluoromethylcholine PET/CT to prostate-specific antigen over different plasma levels. Nuclear Medicine Communications, 2019, 40, 258-263.	1.1	3
6	11C-choline PET/CT predicts survival in prostate cancer patients with PSA ≤ 1 NG/ml. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 921-929.	6.4	14
7	Amyloid burden identifies neuropsychological phenotypes at increased risk of progression to Alzheimer's disease in mild cognitive impairment patients. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 288-296.	6.4	21
8	[68Ga]-Dota Peptide PET/CT in Neuroendocrine Tumors: Main Clinical Applications. Current Radiopharmaceuticals, 2019, 12, 11-22.	0.8	6
9	The relationship between local recurrences and distant metastases in prostate cancer: can 11C-choline PET/CT contribute to understand the link?. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 962-969.	6.4	1
10	Stroke chameleon (cortical hand syndrome) in a patient with moderate carotid stenosis: a neurological double-trouble. Neurological Sciences, 2018, 39, 1125-1127.	1.9	1
11	Will 68 Ga PSMA-radioligands be the only choice for nuclear medicine in prostate cancer in the near future? A clinical update. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018, 37, 103-109.	0.2	0
12	¿Constituir en el futuro los radioligandos de 68 Ga-PSMA la única elección de la Medicina Nuclear para el cáncer de próstata? Actualización clínica. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018, 37, 103-109.	0.0	3
13	Imaging of immunotherapy response in non-small cell lung cancer: challenges and perspectives. Clinical and Translational Imaging, 2018, 6, 483-485.	2.1	8
14	PET/CT With 68Ga-PSMA in Prostate Cancer: Radiopharmaceutical Background and Clinical Implications. Current Radiopharmaceuticals, 2018, 11, 4-13.	0.8	28
15	PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1751-1776.	6.4	45
16	Molecular Imaging of Huntington's Disease. Journal of Cellular Physiology, 2017, 232, 1988-1993.	4.1	6
17	Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study. Journal of Endocrinological Investigation, 2017, 40, 1265-1269.	3.3	4
18	Diagnostic Applications of Nuclear Medicine: Brain Tumors. , 2017, , 467-505.		1

#	ARTICLE	IF	CITATIONS
19	Targeted Therapy Towards Cancer-A Perspective. Anti-Cancer Agents in Medicinal Chemistry, 2017, 17, 311-317.	1.7	13
20	Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer. Current Radiopharmaceuticals, 2017, 10, 6-15.	0.8	8
21	PET/MR Tomographs: A Review with Technical, Radiochemical and Clinical Perspectives. Current Radiopharmaceuticals, 2017, 10, 184-194.	0.8	6
22	11C-Choline PET/CT based Helical Tomotherapy as Treatment Approach for Bone Metastases in Recurrent Prostate Cancer Patients. Current Radiopharmaceuticals, 2017, 10, 195-202.	0.8	5
23	Diagnostic Applications of Nuclear Medicine: Pediatric Cancers. , 2017, , 1103-1137.		0
24	Hybrid Imaging in Pediatric Central Nervous System Disorders. , 2016, , 195-217.		0
25	PET/CT Versus PET/MRI. , 2016, , 297-310.		1
26	How reliable is 18FDG PET for predicting the onset of Huntingtonâ€™s disease?. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2180-2182.	6.4	2
27	Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma. Annals of Nuclear Medicine, 2016, 30, 234-241.	2.2	11
28	Hybrid Imaging in Cerebrovascular Disease: Ischemic Stroke. , 2016, , 251-262.		0
29	Diagnostic Applications of Nuclear Medicine: Brain Tumors. , 2016, , 1-40.		0
30	Multimodality Imaging of Huntingtonâ€™s Disease. , 2016, , 221-230.		0
31	FDG-PET in the Evaluation of Brain Metabolic Changes Induced by Cognitive Stimulation in aMCI Subjects. Current Radiopharmaceuticals, 2015, 8, 69-75.	0.8	16
32	Early detection of encephalitis with 18F-FDG PET/CT. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2015, 34, 188-190.	0.0	1
33	Performance comparison of two resolution modeling PET reconstruction algorithms in terms of physical figures of merit used inÂquantitative imaging. Physica Medica, 2015, 31, 468-475.	0.7	19
34	Post-therapy normalization of brain FDG-PET in Morvan's syndrome. Journal of the Neurological Sciences, 2015, 353, 175-176.	0.6	4
35	Nuclear medicine training and practice in Italy. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1945-1947.	6.4	1
36	Clinical Applications of Choline PET/CT in Brain Tumors. Current Pharmaceutical Design, 2014, 21, 121-127.	1.9	40

#	ARTICLE	IF	CITATIONS
37	Hybrid SPECT/CT Imaging in Neurology. Current Radiopharmaceuticals, 2014, 7, 5-11.	0.8	12
38	Perspectives on PET/MR Imaging: Are We Ready for Clinical Use?. Journal of Nuclear Medicine, 2014, 55, 529-530.	5.0	10
39	From Homo sapiens to Homo in nexu (connected man): could functional imaging redefine the brain of a "new human species"? European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1385-1387.	6.4	6
40	SPECT Radiopharmaceuticals for Dementia. Current Radiopharmaceuticals, 2014, 6, 192-207.	0.8	3
41	Parametric MR Dynamic Imaging for Breast Lesions Characterization and Prediction of Lymph Nodes Involvement. Current Radiopharmaceuticals, 2014, 7, 91-99.	0.8	1
42	Microalbuminuria predicts silent myocardial ischaemia in type 2 diabetes patients. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 548-557.	6.4	13
43	Multiagent imaging of the brain. Clinical and Translational Imaging, 2013, 1, 365-376.	2.1	2
44	Pediatric Cancers. , 2013, , 663-687.		0
45	Weighted registration of ¹²³ I-â€‹FP-â€‹IT SPECT images improves accuracy of binding potential estimates in pathologically low striatal uptake. Journal of Cellular Physiology, 2013, 228, 2086-2094.	4.1	7
46	18F-fluorodeoxyglucose-PET as a biomarker in Huntingtonâ€™s disease. Neurodegenerative Disease Management, 2013, 3, 489-491.	2.2	0
47	Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases. PLoS ONE, 2013, 8, e74548.	2.5	76
48	Auditory Hallucinations as the Only Presenting Symptom of Right-Parietal Spontaneous Hemorrhage: FDG-PET Evidence of Corpus Callosum Hyperactivity. Journal of Neuropsychiatry and Clinical Neurosciences, 2012, 24, E28-E29.	1.8	3
49	PET/MRI and the revolution of the third eye. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1519-1524.	6.4	35
50	18F-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-onset independently of CAG expansion size. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1030-1036.	6.4	60
51	Early defect of transforming growth factor Î²1 formation in Huntingtonâ€™s disease. Journal of Cellular and Molecular Medicine, 2011, 15, 555-571.	3.6	64
52	Seeking Brain Biomarkers for Preventive Therapy in Huntington Disease. CNS Neuroscience and Therapeutics, 2011, 17, 368-386.	3.9	21
53	Imaging of neuroinflammation. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 2198-2201.	6.4	11
54	Caudate glucose hypometabolism in a subject carrying an unstable allele of intermediate CAG ₃₃ repeat length in the Huntington's disease gene. Movement Disorders, 2011, 26, 925-927.	3.9	24

#	ARTICLE	IF	CITATIONS
55	PET translates neurophysiology into images: A review to stimulate a network between neuroimaging and basic research. <i>Journal of Cellular Physiology</i> , 2011, 226, 948-961.	4.1	16
56	Targeted α Therapy and Imaging Response: A New Paradigm For Clinical Evaluation?. <i>Reviews on Recent Clinical Trials</i> , 2011, 6, 259-265.	0.8	18
57	Key role of nuclear medicine in seeking biomarkers of Huntington's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1124-1127.	6.4	13
58	Cerebral Blood Flow in Depressed Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2010, 37, 1844-1851.	2.0	20
59	Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1113-1120.	6.4	52
60	Distinct Brain Volume Changes Correlating with Clinical Stage, Disease Progression Rate, Mutation Size, and Age at Onset Prediction as Early Biomarkers of Brain Atrophy in Huntington's Disease. <i>CNS Neuroscience and Therapeutics</i> , 2009, 15, 1-11.	3.9	69
61	Unexpected Detection of Melanoma Brain Metastasis by PET With Iodine-124 β CIT. <i>Clinical Nuclear Medicine</i> , 2009, 34, 698-699.	1.3	13
62	De novo seven extra repeat expanded mutation in the PRNP gene in an Italian patient with early onset dementia. <i>BMJ Case Reports</i> , 2009, 2009, bcr0820080711-bcr0820080711.	0.5	2
63	Neuroprotective effects of riluzole in Huntington's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 221-222.	6.4	9
64	SOM230, A New Somatostatin Analogue, Is Highly Effective in the Therapy of Growth Hormone/Prolactin-Secreting Pituitary Adenomas. <i>Clinical Cancer Research</i> , 2007, 13, 2738-2744.	7.0	39
65	De novo seven extra repeat expanded mutation in the PRNP gene in an Italian patient with early onset dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1411-1413.	1.9	8
66	The search for cerebral biomarkers of Huntington's disease: a review of genetic models of age at onset prediction. <i>European Journal of Neurology</i> , 2006, 13, 408-415.	3.3	15
67	HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. <i>Cancer Cell</i> , 2006, 9, 459-471.	16.8	226
68	Juvenile Huntington's disease: Does a dosage-effect pathogenic mechanism differ from the classical adult disease?. <i>Mechanisms of Ageing and Development</i> , 2006, 127, 208-212.	4.6	62
69	Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. <i>Journal of Nuclear Medicine</i> , 2006, 47, 215-22.	5.0	201
70	Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. <i>Oncogene</i> , 2005, 24, 3427-3435.	5.9	137
71	Inhibition of early ^{99m}Tc -MIBI uptake by Bcl-2 anti-apoptotic protein overexpression in untreated breast carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 879-887.	6.4	30
72	Italian Huntington disease patients-data and tissue bank. <i>Neurological Sciences</i> , 2003, 24, 215-216.	1.9	5

#	ARTICLE	IF	CITATIONS
73	Brain tissue volume changes in relapsing-remitting multiple sclerosis: correlation with lesion load. <i>NeuroImage</i> , 2003, 18, 360-366.	4.2	82
74	Stereotaxy-Based Regional Brain Volumetry Applied to Segmented MRI: Validation and Results in Deficit and Nondeficit Schizophrenia. <i>NeuroImage</i> , 2002, 17, 373-384.	4.2	49
75	Similar TIAs and corresponding alterations in regional cerebral perfusion in Caucasian monozygotic twins with moyamoya disease. <i>Clinical Imaging</i> , 2002, 26, 378-381.	1.5	4
76	Dynamic coupling of 99mTc-MIBI efflux and apoptotic pathway activation in untreated breast cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 809-814.	6.4	16
77	Assessment of scanner performance and normalization of estimated relaxation rate values. <i>Magnetic Resonance Imaging</i> , 2001, 19, 123-128.	1.8	1
78	Measurement of global brain atrophy in alzheimer's disease with unsupervised segmentation of spin-echo MRI studies. <i>Journal of Magnetic Resonance Imaging</i> , 2000, 11, 260-266.	3.4	27
79	Automated segmentation and measurement of global white matter lesion volume in patients with multiple sclerosis. <i>Journal of Magnetic Resonance Imaging</i> , 2000, 12, 799-807.	3.4	91
80	Scintigraphic Detection of Multidrug Resistance in Cancer. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2000, 15, 327-337.	1.0	31
81	Moyamoya disease in Italian monozygotic twins. <i>Neurology</i> , 1999, 53, 1332-1332.	1.1	23
82	Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 1998, 16, 1677-1683.	1.6	146
83	In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 150-159.	2.1	150
84	Neurologic complications of Hodgkin's disease: A case history. <i>Annals of Oncology</i> , 1997, 8, 593-600.	1.2	5
85	White matter lesion detection in multiple sclerosis: improved interobserver concordance with multispectral MRI display. <i>Journal of Neurology</i> , 1997, 244, 586-590.	3.6	9
86	Unsupervised, automated segmentation of the normal brain using a multispectral relaxometric magnetic resonance approach. <i>Magnetic Resonance in Medicine</i> , 1997, 37, 84-93.	3.0	89
87	Multiparametric display of spin-echo data from MR studies of brain. <i>Journal of Magnetic Resonance Imaging</i> , 1995, 5, 217-225.	3.4	27
88	Assessment of left ventricular regional function by radionuclide angiography: Effects of number of sectors on repeatability. <i>Nuclear Medicine and Biology</i> , 1994, 21, 883-887.	0.6	2
89	Effects of induced asynchrony on left ventricular diastolic function in patients with coronary artery disease. <i>Journal of the American College of Cardiology</i> , 1993, 21, 1124-1131.	2.8	73
90	Simultaneous Display of Multiple MR Parameters with "Quantitative Magnetic Color Imaging". <i>Journal of Computer Assisted Tomography</i> , 1992, 16, 634-640.	0.9	23

#	ARTICLE	IF	CITATIONS
91	Left ventricular diastolic function in systemic sclerosis: assessment by radionuclide angiography. Journal of Nuclear Medicine, 1992, 33, 68-72.	5.0	9
92	Assessment of left ventricular diastolic function: comparison of contrast ventriculography and equilibrium radionuclide angiography. Journal of Nuclear Medicine, 1991, 32, 1849-53.	5.0	8
93	Effects of intravenous verapamil on left ventricular relaxation and filling in stable angina pectoris. American Journal of Cardiology, 1990, 66, 818-825.	1.6	17